logo-loader
viewOmega Diagnostics Group PLC

Omega Diagnostics to expand manufacturing capacity as it scales up coronavirus test development

Omega Diagnostics CEO (LON:ODX) Colin King introduces the business to Proactive London's Andrew Scott and its main areas of focus - CD4, infectious diseases and food intolerance testing. He says while some areas of the business have been slowed by the pandemic they're rapidly developing new tests for COVID-19 that will need to be made and sold in significant volume.

Quick facts: Omega Diagnostics Group PLC

Price: 51.65 GBX

AIM:ODX
Market: AIM
Market Cap: £90.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HANeft's Kuwait partner says country's inclusion on MSCI Index signals...

Abdullah Al-Busairi, the Director of KMEFIC which has partnered with HANeft for its Kuwait product, explains to Proactive's Andrew Scott the significance of the country being included on the MSCI Emerging Market index in November. The KMEFICFTSE Kuwait Equity UCITS ETF (KUW8) tracks the FTSE...

26 minutes ago

2 min read